Role of the VEGF Ligand to Receptor Ratio in the Progression of Mismatch Repair-proficient Colorectal Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 Mar 13

PMID 20222950

Citations 8

Authors

Manuela Eppenberger

Inti Zlobec

Daniel Baumhoer

Luigi Terracciano

Alessandro Lugli

Affiliations

Soon will be listed here.

Abstract

Background: The VEGF family of ligands and receptors are intimately involved in tumor angiogenesis, lymphangiogenesis and metastasis. The evaluation of VEGF ligand/receptor ratios may provide a more profound understanding of the involvement of these proteins in colorectal tumour progression. The aim of this study was to elucidate the role of the VEGF ligand/receptor ratios on tumour progression and metastasis in patients with mismatch repair-proficient colorectal cancer.

Methods: Immunohistochemistry for VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR1, VEGFR2 and VEGF3 was carried out on 387 mismatch repair-proficient colorectal cancers using a tissue microarray. Evaluation of immunoreactivity was performed semi-quantitatively and the ligand/receptor expression ratio was obtained.

Results: An increased VEGF-A/VEGFR1 ratio, VEGF-A and VEGFR1 was linked to the presence of peritumoral lymphocytic inflammation at the invasive front (p = 0.032; p = 0.005; p = 0.032, respectively). VEGFR1 expression was related to poorer outcome in multivariable analysis with pT stage, pN stage, vascular invasion, and post-operative therapy. A higher ratio of VEGF-A/VEGFR2 was linked to advanced TNM stage (p = 0.005) while VEGF-A and VEGFR2 were elevated in tumours with an infiltrating tumour growth pattern (p = 0.006; p = 0.014; p = 0.006). No effect of VEGF-A/VEGFR2, VEGF-A or VEGFR2 on survival time was noted.

Conclusions: Our findings highlight an involvement of VEGF-A, VEGR1 and VEGFR2 in events occurring at the invasive tumour front and a potential prognostic role of VEGFR1 expression in mismatch repair-proficient colorectal cancers. The VEGF-A ligand to VEGFR1 or VEGFR2 ratio may represent an alternative evaluation system for identifying patients with poorer clinical outcome.

Citing Articles

Co-reactivity pattern of glucose metabolism and blood perfusion revealing DNA mismatch repair deficiency based on PET/DCE-MRI in endometrial cancer.

Li X, Cui B, Wang S, Gao M, Xing Q, Liu H Cancer Imaging. 2024; 24(1):161.

PMID: 39582001 PMC: 11587675. DOI: 10.1186/s40644-024-00805-5.

Inflammation- and Metastasis-Related Proteins Expression Changes in Early Stages in Tumor and Non-Tumor Adjacent Tissues of Colorectal Cancer Samples.

Alorda-Clara M, Torrens-Mas M, Hernandez-Lopez R, Ibarra de la Rosa J, Falco E, Fernandez T Cancers (Basel). 2022; 14(18).

PMID: 36139645 PMC: 9497293. DOI: 10.3390/cancers14184487.

The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer.

DHaene N, Koopmansch C, Van Eycke Y, Hulet F, Allard J, Bouri S Int J Mol Sci. 2018; 19(11).

PMID: 30423986 PMC: 6274874. DOI: 10.3390/ijms19113536.

MGOGP: a gene module-based heuristic algorithm for cancer-related gene prioritization.

Su L, Liu G, Bai T, Meng X, Ma Q BMC Bioinformatics. 2018; 19(1):215.

PMID: 29871590 PMC: 5989416. DOI: 10.1186/s12859-018-2216-0.

Cell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis.

Jayasinghe C, Simiantonaki N, Kirkpatrick C BMC Cancer. 2015; 15:104.

PMID: 25880726 PMC: 4384349. DOI: 10.1186/s12885-015-1130-3.

References

Kondo Y, Arii S, Mori A, Furutani M, Chiba T, Imamura M . Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line. Clin Cancer Res. 2000; 6(2):622-30. View

Hanrahan V, Currie M, Gunningham S, Morrin H, Scott P, Robinson B . The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol. 2003; 200(2):183-94. DOI: 10.1002/path.1339. View

Lee J, Chow N, Wang S, Huang S . Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer. 2000; 36(6):748-53. DOI: 10.1016/s0959-8049(00)00003-4. View

Bruns C, Liu W, Davis D, Shaheen R, McConkey D, Wilson M . Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer. 2000; 89(3):488-99. View

Neuchrist C, Erovic B, Handisurya A, Steiner G, Rockwell P, Gedlicka C . Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope. 2002; 111(10):1834-41. DOI: 10.1097/00005537-200110000-00031. View

Ghanem M, van Steenbrugge G, Sudaryo M, Mathoera R, Nijman J, Van der Kwast T . Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol. 2003; 56(2):107-13. PMC: 1769871. DOI: 10.1136/jcp.56.2.107. View

Compton C . Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol. 2003; 16(4):376-88. DOI: 10.1097/01.MP.0000062859.46942.93. View

Kawakami M, Furuhata T, Kimura Y, Yamaguchi K, Hata F, Sasaki K . Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer. J Exp Clin Cancer Res. 2003; 22(2):229-37. View

Bates R, Goldsmith J, Bachelder R, Brown C, Shibuya M, Oettgen P . Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol. 2003; 13(19):1721-7. DOI: 10.1016/j.cub.2003.09.002. View

10.

Sauter G, Simon R, Hillan K . Tissue microarrays in drug discovery. Nat Rev Drug Discov. 2003; 2(12):962-72. DOI: 10.1038/nrd1254. View

11.

Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S, Chayama K . Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci. 2004; 95(1):32-9. PMC: 11159672. DOI: 10.1111/j.1349-7006.2004.tb03167.x. View

12.

Mukhopadhyay D, Datta K . Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol. 2004; 14(2):123-30. DOI: 10.1016/j.semcancer.2003.09.019. View

13.

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

14.

Folkman J, Merler E, Abernathy C, Williams G . Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971; 133(2):275-88. PMC: 2138906. DOI: 10.1084/jem.133.2.275. View

15.

Jass J, Love S, Northover J . A new prognostic classification of rectal cancer. Lancet. 1987; 1(8545):1303-6. DOI: 10.1016/s0140-6736(87)90552-6. View

16.

Plate K, Breier G, Weich H, Mennel H, Risau W . Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer. 1994; 59(4):520-9. DOI: 10.1002/ijc.2910590415. View

17.

Takahashi Y, Kitadai Y, Bucana C, Cleary K, Ellis L . Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995; 55(18):3964-8. View

18.

Kang S, Maeda K, Onoda N, Chung Y, Nakata B, Nishiguchi Y . Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer. 1997; 74(5):502-7. DOI: 10.1002/(sici)1097-0215(19971021)74:5<502::aid-ijc4>3.0.co;2-7. View

19.

Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H . Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer. 1998; 77(6):998-1002. PMC: 2150098. DOI: 10.1038/bjc.1998.164. View

20.

Nakata S, Ito K, Fujimori M, Shingu K, Kajikawa S, Adachi W . Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers. Int J Cancer. 1998; 79(2):179-86. DOI: 10.1002/(sici)1097-0215(19980417)79:2<179::aid-ijc14>3.0.co;2-5. View